XDXian-Zhong Ding

Xian-Zhong Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xian-Zhong Ding has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unravelling the mechanics of knitted fabrics through hierarchical geometric representation

    by Xiaoxiao Ding, Vanessa Sanchez, Katia Bertoldi, Chris H. Rycroft

    Knitting interloops one-dimensional yarns into three-dimensional fabrics that exhibit behaviour beyond their constitutive materials. How extensibility and anisotropy emerge from the hierarchical organization of yarns into knitted fabrics has long been unresolved. We seek to unravel the mechanical roles of tensile mechanics, assembly and dynamics arising from the yarn level on fabric nonlinearity by developing a yarn-based dynamical model. This physically validated model captures the mechanical response of knitted fabrics, analogous to flexible metamaterials and biological fibre networks due to geometric nonlinearity within such hierarchical systems. Fabric anisotropy originates from observed yarn–yarn rearrangements during alignment dynamics and is topology-dependent. This yarn-based model also provides a design space of knitted fabrics to embed functionalities by varying geometric configuration and material property in instructed procedures compatible to machine manufacturing. Our hierarchical approach to build up a knitted fabric computationally modernizes an ancient craft and represents a first step towards mechanical programmability of knitted fabrics in wide engineering applications.


  • Open Access

    On the role of transforming growth factor-β in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells

    by Brahmchetna Singh, Richard F Murphy, Xian-Zhong Ding, Alexandra B Roginsky, Richard H Bell, Thomas E Adrian

    Background: Retinoids are potent growth inhibitory and differentiating agents in a variety of cancer cell types. We have shown that retinoids induce growth arrest in all pancreatic cancer cell lines studied, regardless of their p53 and differentiation status. However, the mechanism of growth inhibition is not known. Since TGF-β2 is markedly induced by retinoids in other cancers and mediates MUC4 expression in pancreatic cancer cells, we investigated the role of TGF-β in retinoic acid-mediated growth inhibition in pancreatic cancer cells. Results: Retinoic acid markedly inhibited proliferation of two cell lines (Capan-2 and Hs766T) in a concentration and time-dependent manner. Retinoic acid increased TGF-β2 mRNA content and secretion of the active and latent forms of TGF-β2 (measured by ELISA and bioassay). The concentrations of active and TGF-β2 secreted in response to 0.1 – 10 μM retinoic acid were between 1–5 pM. TGF-β2 concentrations within this range also inhibited proliferation. A TGF-β neutralizing antibody blocked the growth inhibitory effects of retinoic acid in Capan-2 cells and partially inhibitory the effects in Hs766T cells. Conclusion: These findings indicate that TGF-β can cause growth inhibition of pancreatic cancer cells, in a p53-independent manner. Furthermore, it demonstrates the fundamental role of TGF-β in growth inhibition in response to retinoic acid treatment is preserved in vitro.


  • Open Access

    Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest

    by Michael B Ujiki, Xian-Zhong Ding, M Reza Salabat, David J Bentrem, Laleh Golkar, Ben Milam, Mark S Talamonti, Richard H BellJr, Takeshi Iwamura, Thomas E Adrian

    Background: Many chemotherapeutic agents have been used to treat pancreatic cancer without success. Apigenin, a naturally occurring flavonoid, has been shown to inhibit growth in some cancer cell lines but has not been studied in pancreatic cancer. We hypothesized that apigenin would inhibit pancreatic cancer cell growth in vitro. Results: Apigenin caused both time- and concentration-dependent inhibition of DNA synthesis and cell proliferation in four pancreatic cancer cell lines. Apigenin induced G2/M phase cell cycle arrest. Apigenin reduced levels of cyclin A, cyclin B, phosphorylated forms of cdc2 and cdc25, which are all proteins required for G2/M transition. Conclusion: Apigenin inhibits growth of pancreatic cancer cells through suppression of cyclin B-associated cdc2 activity and G2/M arrest, and may be a valuable drug for the treatment or prevention of pancreatic cancer.


  • Open Access

    Pancreatic Stellate Cells (PSCs) express Cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs

    by Seiya Yoshida, Michael Ujiki, Xian-Zhong Ding, Carolyn Pelham, Mark S Talamonti, Richard H BellJr, Woody Denham, Thomas E Adrian

    Cyclooxygenase 2 (COX-2), the inducible form of prostaglandin G/H synthase, is associated with several human cancers including pancreatic adenocarcinoma. Pancreatic stellate cells (PSCs) play a central role in the intense desmoplasia that surrounds pancreatic adenocarcinoma. The present study examined COX-2 expression in PSCs. PSCs isolated from normal rats, were cultured and exposed to conditioned medium (CM) from the human pancreatic cell line, PANC-1.